Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "LAC"

1338 News Found

DRDO places orders for oxygen generators with 10 companies
Public Health | September 16, 2021

DRDO places orders for oxygen generators with 10 companies

Godrej and Boyce and Isgec Engineering have confirmed receiving the orders


Shalby Hospital opens its first orthopaedic and joint replacement franchisee in Udaipur, Rajasthan
Hospitals | September 13, 2021

Shalby Hospital opens its first orthopaedic and joint replacement franchisee in Udaipur, Rajasthan

The hospital through its network performs more than 10,000 joint replacement surgeries annually


Jubilant Pharmova’s Roorkee facility placed under import alert
News | July 16, 2021

Jubilant Pharmova’s Roorkee facility placed under import alert

The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.


Five manufacturers get license to produce Black Fungus drug
News | May 23, 2021

Five manufacturers get license to produce Black Fungus drug

NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers


RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer
Diagnostic Center | July 03, 2025

RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer

Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.


India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil
Policy | July 02, 2025

India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil

Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future


INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease
Diagnostic Center | July 02, 2025

INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease

Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients


Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer
Diagnostic Center | July 01, 2025

Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options


FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels
Drug Approval | June 28, 2025

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access